INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Sweat chloride equal or greater than 60 mEq/L by   │ Sweat chloride equal or greater than 60 mEq/L by   │     100 │
│ quantitative pilocarpine iontophoresis test        │ quantitative pilocarpine iontophoresis test        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Two well-characterized mutations in the cystic     │ Two well-characterized mutations in the cystic     │     100 │
│ fibrosis transmembrane conductance regulator       │ fibrosis transmembrane conductance regulator       │         │
│ (CFTR) gene                                        │ (CFTR) gene                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Abnormal nasal potential difference (NPD) as       │ Abnormal nasal potential difference (NPD) as       │     100 │
│ measured by a change in NPD in response to a low   │ measured by a change in NPD in response to a low   │         │
│ chloride solution and isoproterenol of less than   │ chloride solution and isoproterenol of less than   │         │
│ -5 mV                                              │ -5 mV                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Documentation of the presence of an acute          │ Documentation of the presence of an acute          │     100 │
│ pulmonary exacerbation, based on CF Foundation     │ pulmonary exacerbation, based on CF Foundation     │         │
│ guidelines, as diagnosed by a faculty member of    │ guidelines, as diagnosed by a faculty member of    │         │
│ the Denver Adult CF Program                        │ the Denver Adult CF Program                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Respiratory culture(s) demonstrating evidence of   │ Respiratory culture(s) demonstrating evidence of   │     100 │
│ Pseudomonas aeruginosa or Achromobacter species    │ Pseudomonas aeruginosa or Achromobacter species    │         │
│ airway infection                                   │ airway infection                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject is able to produce sputum, undergo         │ Subject is able to produce sputum, undergo         │     100 │
│ phlebotomy, and provide written consent            │ phlebotomy, and provide written consent            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The subject's treating physician has determined    │ The subject's treating physician has determined    │     100 │
│ that they should receive either tobramycin or      │ that they should receive either tobramycin or      │         │
│ colistin intravenously as one of the designated    │ colistin intravenously as one of the designated    │         │
│ agents for their APE treatment. Subjects who are   │ agents for their APE treatment. Subjects who are   │         │
│ able to receive either tobramycin or colistin as   │ able to receive either tobramycin or colistin as   │         │
│ part of their antibiotic regimen will be           │ part of their antibiotic regimen will be           │         │
│ randomized into one of three arms. If a treating   │ randomized into one of three arms. If a treating   │         │
│ physician deems that a subject cannot receive      │ physician deems that a subject cannot receive      │         │
│ tobramycin due to vestibular toxicity, ototoxicity │ tobramycin due to vestibular toxicity, ototoxicity │         │
│ or bacterial resistance, the subject will be       │ or bacterial resistance, the subject will be       │         │
│ randomized to either standard or PK-adjusted       │ randomized to either standard or PK-adjusted       │         │
│ colistin                                           │ colistin                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male or female ≥ 18 years of age at Visit 1        │ Male or female = 18 years of age at Visit 1        │      98 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                    │   Score │
╞════════════════════════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Presence of chronic renal insufficiency, with      │ Male or female = 18 years of age at Visit 1      │      36 │
│ abnormal baseline creatinine \>1.2mg/dL            │                                                  │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Inability to expectorate sputum. -                 │ Male or female = 18 years of age at Visit 1      │      36 │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Inability to perform reproducible spirometry       │ Subject is able to produce sputum, undergo       │      38 │
│                                                    │ phlebotomy, and provide written consent          │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Concomitant administration of bactrim (due to      │ Respiratory culture(s) demonstrating evidence of │      39 │
│ effects on creatinine)                             │ Pseudomonas aeruginosa or Achromobacter species  │         │
│                                                    │ airway infection                                 │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients being treated for B. cepacia, due to      │ Two well-characterized mutations in the cystic   │      41 │
│ colistin resistance by the pathogen                │ fibrosis transmembrane conductance regulator     │         │
│                                                    │ (CFTR) gene                                      │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Male or female = 18 years of age at Visit 1      │      42 │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Concomitant administration of inhaled colistin for │ Two well-characterized mutations in the cystic   │      42 │
│ patients in the colistin PK arm, as this will      │ fibrosis transmembrane conductance regulator     │         │
│ create inaccuracies in colistin sputum             │ (CFTR) gene                                      │         │
│ concentration measurements                         │                                                  │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Documentation of CF diagnosis as evidenced by one  │ Documentation of the presence of an acute        │      45 │
│ or more clinical features consistent with the CF   │ pulmonary exacerbation, based on CF Foundation   │         │
│ phenotype and one or more of the following         │ guidelines, as diagnosed by a faculty member of  │         │
│ criteria                                           │ the Denver Adult CF Program                      │         │
├────────────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Presence of a condition or abnormality that in the │ Documentation of the presence of an acute        │      45 │
│ opinion of the investigator would compromise the   │ pulmonary exacerbation, based on CF Foundation   │         │
│ safety of the patient or the quality of the data   │ guidelines, as diagnosed by a faculty member of  │         │
│                                                    │ the Denver Adult CF Program                      │         │
╘════════════════════════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒══════════════════════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                                │ CHIA Criteria   │   Score │
╞══════════════════════════════════════════════════╪═════════════════╪═════════╡
│ Respiratory culture(s) demonstrating evidence of │ NA              │       2 │
│ Pseudomonas aeruginosa or Achromobacter species  │                 │         │
│ airway infection                                 │                 │         │
╘══════════════════════════════════════════════════╧═════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 76
Average Levenshtein Ratio of individual lines: 64.66666666666667
OverAll Ratio: 70.33333333333334
